3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
163
Breast Neoplasms
162
Carcinoma, Non-Small-Cell Lung
60
Melanoma
44
Ovarian Neoplasms
42
Colorectal Neoplasms
37
Carcinoma, Renal Cell
36
Squamous Cell Carcinoma of Head and Neck
33
Pancreatic Neoplasms
29
Stomach Neoplasms
28
Neoplasm Metastasis
27
Uterine Cervical Neoplasms
24
Neoplasms
24
Endometrial Neoplasms
24
Lung Neoplasms
19
Head and Neck Neoplasms
19
Esophageal Neoplasms
18
Carcinoma, Transitional Cell
18
Carcinoma, Hepatocellular
16
Urinary Bladder Neoplasms
14
Small Cell Lung Carcinoma
14
Prostatic Neoplasms
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Sarcoma
10
Mesothelioma
9
Kidney Neoplasms
9
Cholangiocarcinoma
9
Carcinoma, Ovarian Epithelial
9
Carcinoma, Merkel Cell
9
Fallopian Tube Neoplasms
8
Interventions
Mammography
4
Magnetic Resonance Spectroscopy
3
pembrolizumab
1
Vertical Dimension
1
Therapeutics
1
TKM-080301
1
Surveys and Questionnaires
1
Sensitivity Training Groups
1
Self-Management
1
Referral and Consultation
1
Quality of Life
1
Professional Autonomy
1
Patient Positioning
1
Paclitaxel
1
Methylene Blue
1
Mass Screening
1
Magnetic Resonance Imaging
1
Interviews as Topic
1
Interleukin-15
1
Gemcitabine
1
Exercise
1
Drug Delivery Systems
1
Doxorubicin
1
Counseling
1
Blood Specimen Collection
1
Biopsy
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
pembrolizumab
×
Breast
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled